artemether/vėmimas

Nuoroda įrašoma į mainų sritį

Pasirinkite rūšiavimo tipą

12 rezultatus

In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children (MEFI_III)

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

This study followed WHO recommendations for in vivo antimalarial efficacy trials. The study population comprised children aged 6 to 59 months with microscopically confirmed acute uncomplicated malaria. Other inclusion criteria included body weight ≥5kg, the presence of fever (≥37.5°C axillary) or a

TES Artemether-lumefantrine for Pf and Chloroquine (CQ) for Pv

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

1. BACKGROUND In 2002, the Philippines changed its antimalarial drug policy to the combination treatment, CQ+ Sulphadoxine-pyrimethamine (SP) as 1st-line treatment and artemether-lumefantrine as 2nd-line treatment. The Department of Health (DOH) prescribed the use of artemether-lumefantrine (AL)

Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Combination therapy, the new strategy for malaria treatment, is based on the hypothesis that two (or more) components of different mechanisms of action protect each other from development of resistance. Artemisinin as well as its two derivatives, e.g. artemether and artesunate, constitute a family

Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Malaria incidence has increased two- to three-folds over the past four decades, and nearly half the world's population now lives in regions endemic for malaria: In Asia, Africa, and South America. A global annual estimate of 300-500 clinical cases of malaria and mortality in the range of 1-2 million

Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

3.1 STUDY DESIGN Children with uncomplicated malaria meeting the inclusion criteria will be enrolled (after their parent/caretaker has given informed consent), treated on site with the drugs under evaluation and followed-up for a period of 42 days. Drugs will be given under direct supervision,

In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Methodology Children of either gender, between 6 months (> 5kg) and 10 years of age, with acute uncomplicated P. falciparum infection, who fulfil all of the inclusion and have none of exclusion criteria will be enrolled in the study. They will be randomised to receive the three trial arms, i.e,

Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Background Plasmodium falciparum causes malaria and approximately 665 000 deaths each year. Previously chloroquine (CQ) and sulphadoxine-pyrimethamine were the principle drugs for the treatment of malaria. Due to widespread resistance to these drugs1, the World Health Organization recommends that P.

Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Background : RIAMET® or Malarone® are both recommended as the first line treatment for uncomplicated malaria in France, according to the French consensus Conference revised in 2007 on the treatment of imported malaria. Today no randomized controlled trial (RCT) comparing both treatments are

Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated P.Falciparum Malaria in Children

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

An open label uncontrolled study to determine the efficacy of fosmidomycin and clindamycin when co-administered orally over three days in the treatment of acute uncomplicated Plasmodium falciparum malaria in children. The primary study endpoints will be the cure rate on Day 28 (PCR corrected). The

Comparison of Three Drug Combinations for Intermittent Treatment of Malaria in Children

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Objectives Primary Objective To determine the safety and tolerability of amodiaquine(AQ) (three days) plus sulfadoxine-pyrimethamine(SP) (one day), piperaquine(PQP) (three days) plus SP (one day), and Artekin TM (PQP plus dihydroartemisinin, DHA) (3 days) when used for seasonal IPT in

Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Primary objective: To assess the level of resistance to artemisinin derivatives in Western Cambodia. Secondary objective: To assess the level of resistance to other antimalarial drugs in Western Cambodia 1. Background; There are worrying signs from Western Cambodia that parasitological responses to

Prisijunkite prie mūsų
„Facebook“ puslapio

Herbal & Natural Medicine

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais